Enrique M. Ocio, MD, PhD, Marqués de Valdecilla University Hospital, Santander, Spain, shares an update on the Phase I/IIa ANCHOR trial (NCT03481556) investigating melflufen plus dexamethasone with bortezomib or daratumumab in patients with relapsed/refractory multiple myeloma. The overall response rate was 73% in combination with daratumumab, and 62% in bortezomib. Both arms exhibited a similar safety profile to melflufen plus dexamethasone therapy alone. The median progression-free survival (PFS) for combination with daratumumab was 12.9 months at a follow-up of 18.9 months. PFS data is not yet available for the bortezomib arm. This interview took place during the 2021 European Myeloma Network (EMN) congress.